Online inquiry

IVTScrip™ mRNA-Anti-CD3E&FCRL5, BFCR-4350-A(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ3962MR)

This product GTTS-WQ3962MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets CD3E&FCRL5 gene. The antibody can be applied in Multiple myeloma (MM) research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 1
Species Chimeric; Humanized
RefSeq NM_000733.4; NM_001195388.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 916; 83416
UniProt ID P07766; Q96RD9
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD3E&FCRL5, BFCR-4350-A(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) (GTTS-WQ3962MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ468MR IVTScrip™ mRNA-Anti-SELP, 42-89-glycoprotein(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA 42-89-glycoprotein
GTTS-WQ3712MR IVTScrip™ mRNA-Anti-MSLN, BAY 94-9343(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA BAY 94-9343
GTTS-WQ10740MR IVTScrip™ mRNA-Anti-ADAMTSL5&ALB, M-6495(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA M-6495
GTTS-WQ3975MR IVTScrip™ mRNA-Anti-LTB&TNFSF14, BG9924(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA BG9924
GTTS-WQ1092MR IVTScrip™ mRNA-Anti-MAPT, ABBV-8E12(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA ABBV-8E12
GTTS-WQ3138MR IVTScrip™ mRNA-Anti-C3&C4, APT070(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA APT070
GTTS-WQ4577MR IVTScrip™ mRNA-Anti-CD40LG, BMS-986004(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA BMS-986004
GTTS-WQ11153MR IVTScrip™ mRNA-Anti-IFNAR1, MDX-1333(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA MDX-1333
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.